Mosaic Turner syndrome shows reduced phenotypic penetrance in an adult population study compared to clinically ascertained cases
Marcus A. TukeiD, Katherine S. RuthiD, Andrew R. WoodiD, Robin N. BeaumontiD, Jessica TyrrelliD, Samuel E. JonesiD, Hanieh YaghootkariD, Claire Turner, Mollie E. Donohoe, Antonia M. Brooke, Morag N. Collinson, Rachel M. FreathyiD, Michael N. WeedoniD, Timothy M. FraylingiD, Anna MurrayiD
Abstract
Women with X chromosome aneuploidy such as 45,X (Turner syndrome) or 47,XXX (Triple X syndrome) present with characteristics including differences in stature, increased cardiovascular disease risk and primary ovarian insufficiency. Many women with X chromosome aneuploidy undergo lifetime clinical monitoring for possible complications. However, ascertainment of cases in the clinic may mean that the phenotypic penetrance is overestimated. Studies of prenatally ascertained X chromosome aneuploidy cases have limited follow-up data and so the long-term consequences into adulthood are often not reported. We aimed to characterise the prevalence and phenotypic consequences of X chromosome aneuploidy in a large population of women over 40 years of age. We detected 30 women with 45,X, 186 with mosaic 45,X/46,XX and 110 with 47,XXX among 244,848 UK Biobank women, using SNP array data. The prevalence of non-mosaic 45,X (1/8,162) and 47,XXX (1/2,226) was lower than expected, but was higher for mosaic 45,X/46,XX (1/1,316). The characteristics of women with 45,X were consistent with the characteristics of a clinically recognised Turner syndrome phenotype, including a 17.2cm shorter stature (SD = 5.72cm; P = 1.5 x 10-53) and 16/30 did not report an age at menarche. The phenotype of women with 47,XXX included taller stature (5.3cm; SD = 5.52cm; P = 5.8 x 10-20), earlier menopause age (5.12 years; SD = 5.1 years; P = 1.2 x 10-14) and a lower fluid intelligence score (24%; SD = 29.7%; P = 3.7 x 10-8). In contrast, the characteristics of women with mosaic 45,X/46,XX were much less pronounced than expected. Women with mosaic 45,X/46,XX were less short, had a normal reproductive lifespan and birth rate, and no reported cardiovascular complications. In conclusion, the availability of data from 244,848 women allowed us to assess the phenotypic penetrance of traits associated with X chromosome aneuploidy in an adult population setting. Our results suggest that the clinical management of women with 45,X/46,XX mosaicism should be minimal, particularly those identified incidentally.\n\nFundingNone
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 147
- FWCI
- 7.67
- Field percentile
- top 2%
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Relationship between X chromosome mosaicism, neuroanatomy and cognitive performance in females
Iliana I. Karipidis, Megan Klabunde, … David S. Hong·bioRxiv·Feb 10, 2026
- Prevalence and disease risks for male and female sex chromosome trisomies: a registry-based phenome-wide association study in 1.5 million participants of MVP, FinnGen, and UK Biobank
Shanlee Davis, Aoxing Liu, … Richard L. Hauger·medRxiv·Jan 31, 2025
- Genetic mechanisms of mitotic error in 840,853 blood genomes
Yichen Si, Nolan Kamitaki, … Po‐Ru Loh·medRxiv·Sep 9, 2026
- Population analyses of mosaic X chromosome loss identify genetic drivers and widespread signatures of cellular selection
Aoxing Liu, Giulio Genovese, … Mitchell J. Machiela·medRxiv·Jan 28, 2023
- The transcriptomic landscape of monosomy X (45,X) during early human fetal and placental development
Jenifer P. Suntharalingham, Ignacio del Valle, … John C. Achermann·Communications BiologyPeer-reviewed·Feb 16, 2025
- Prevalence, Morbidity, and Mortality of 1,609 Men with Diagnosed and Undiagnosed Sex Chromosome Aneuploidy: Results from the Diverse Million Veteran Program (MVP) Cohort
Shanlee Davis, Craig Carl Teerlink, … Richard L. Hauger·medRxiv·Jul 15, 2023